Result of AGM

RNS Number : 6573C

Ergomed plc

18 June 2019

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Results of 2019 Annual General Meeting

Guildford, UK - 18 June 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting held earlier today.  Resolutions 1 to 6 were duly passed, whilst Resolutions 7 and 8 were not passed.

Resolutions 1 to 5 were passed on a show of hands.  Details of proxy results were as follows:

Resolution number	Votes for	Votes against	Abstentions
1	20,232,290	77,125	8,649
2	20,160,715	156,099	1,250
3	16,997,564	Nil	3,320,500
4	20,316,814	Nil	1,250
5	20,302,774	14,040	1,250

Details of voting results for Resolutions 6, 7 and 8 (including proxies) were as follows:

Resolution number	Votes for	Votes against	Abstentions
6	27,839,992	10,681,500	1,250
7	27,683,893	10,837,599	1,250
8	27,610,768	10,910,724	1,250

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott	[e-mail]
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 

END

 

 

RAGLLFEVRTITLIA